Sección. Artículo original
Postauthorization safety study (NISSO) assessing the long-term safety profile of sonidegib in patients with locally advanced basal cell carcinoma: interim analysis from the Spanish cohort
S. Beà Ardébol1,#, G.M. Pérez Pastor2,#, R. Fernández-de-Misa3, R. Botella Estrada4, V. Ruiz-Salas5, Á. Flórez6, M. Mayor Arenal7, M.J. Fuente González8, P. Bassas-Freixas9, A. Toll Abelló10, P. Valerón Almazán11, R. Arntz12, J. Malvehy Guilera10,13,
Autor para correspondencia
1 Hospital Universitario Ramón y Cajal, Dermatology Department, Madrid, Spain
2 Consorcio Hospital General Universitario de Valencia, Dermatology Department, Valencia, Spain
3 Hospital Universitario Nuestra Señora de Candelaria, Dermatology Department, Santa Cruz de Tenerife, Canary Islands, Spain
4 Hospital Universitari i Politècnic La Fe, Dermatology Service, Valencia, Spain
5 Hospital de la Santa Creu i Sant Pau, Dermatology Department, Barcelona, Spain
6 Complexo Hospitalario Universitario de Pontevedra, Dermatology Department, Pontevedra, Spain
7 Hospital Universitario La Paz, Dermatology Department, Madrid, Spain
8 Hospital Germans Trials i Pujol, Dermatology Department, Badalona, Spain
9 Hospital Universitari Vall d'Hebron, Dermatology Department, Barcelona, Spain
10 Hospital Clínic de Barcelona, Dermatology Department, Barcelona, Spain
11 Hospital Universitario de Gran Canaria Doctor Negrín, Dermatology Service, Las Palmas de Gran Canaria, Canary Islands, Spain
12 Sun Pharmaceutical Industries B.V., Hoofddorp, The Netherlands
13 IDIBAPS, CIBER deEnfermedades Raras, Instituto Carlos III, University of Barcelona, Barcelona, Spain
Ver más
